Anakinra

Combination with TNF blockers including infliximab is not recommended due to increased risk of serious infections with no added clinical benefit.

Combination with TNF blockers increased risk of serious infections with no added clinical benefit. Not recommended due to similar toxicities with TNF blocker therapy.

Combination with anakinra is not recommended due to increased risk of serious infections with no added clinical benefit seen in clinical studies of TNF blockers.

Increased risk of serious infection when combined with TNF blockers; not recommended in RA patients.

Increased risk of serious infection when combined with ADALIMUMAB-AACF. Concomitant use is not recommended in patients with RA.

Increased risk of serious infection with no added benefit. Concomitant use not recommended in patients with RA.

Increased risk of serious infection when combined with adalimumab-adaz. Use not recommended in patients with RA due to no added benefit.

Increased risk of serious infection when combined with adalimumab-adbm. Concomitant use not recommended in patients with RA.

Increased risk of serious infection when combined with TNF blockers. Use not recommended in patients with RA due to no added benefit.

Increased risk of serious infection when combined with YUSIMRY; concomitant use not recommended in RA patients.

Increased risk of serious infection when combined with AMJEVITA. Concomitant use not recommended in RA patients.

Increased risk of serious infection when combined with HADLIMA; not recommended for RA patients.

Increased risk of serious infection when combined with adalimumab-fkjp; combination not recommended in RA patients.

Increased risk of serious infection when combined with adalimumab-ryvk. Not recommended in patients with RA.

Use of KINERET in combination with TNF blocking agents is not recommended due to increased serious infections.

Concomitant use decreases defactinib exposure, which may reduce the effectiveness of the drug combination. Avoid concomitant use.

Triple combination with ACE inhibitor and mineralocorticoid receptor antagonist is generally not recommended. Monitor blood pressure, renal function, and electrolytes.

Triple combination with candesartan cilexetil and an ACE-inhibitor is generally not recommended due to increased risks of hypotension, hyperkalemia, and renal dysfunction.

Increased risk of serious infections when used in combination with TNF-blocking agents. Combination therapy not recommended.

Coadministration may decrease dasatinib concentrations and reduce efficacy. Do not administer with dasatinib.

Coadministration with rilpivirine requires staggered administration due to increased gastric pH potentially decreasing rilpivirine plasma concentrations and loss of virologic response.

Use of RPV with H2-receptor antagonists requires staggered administration to avoid decreased plasma concentrations of RPV and loss of virologic response.

Use of RPV with H2-receptor antagonists requires staggered administration to avoid decreased plasma concentrations of RPV and loss of virologic response.

Concurrent use resulted in 7% rate of serious infections (vs 0% with Enbrel alone), including bacterial pneumonia and cellulitis, without additional clinical benefit.

Increased risk of serious infection when used concomitantly with golimumab. Combination not recommended.

Concomitant use has resulted in serotonin syndrome; carefully observe patient during treatment initiation and dose adjustment.

Concomitant use may result in serotonin syndrome. Frequently evaluate patient during treatment initiation and dose adjustment.

Concomitant use has resulted in serotonin syndrome.

Concomitant use may result in serotonin syndrome. Carefully observe patient during treatment initiation and dosage modification; discontinue metaxalone if serotonin syndrome occurs.

Concomitant use with opioids has resulted in serotonin syndrome.

Concomitant use may result in serotonin syndrome. Carefully observe patient during treatment initiation and dose adjustment.

Concomitant use may decrease neratinib AUC, reducing NERLYNX activity. Separate administration by at least 2 hours before or 10 hours after.

Gastric acid reducing agent. Decreases nirogacestat exposure, which may reduce effectiveness of nirogacestat.

Concomitant use may result in serotonin syndrome.

Concomitant use has resulted in serotonin syndrome. Carefully observe patient during treatment initiation and dose adjustment.

Antagonistic effects with decreased phenylephrine blood pressure effect.

Concomitant use may result in serotonin syndrome.

Concomitant use may reduce the effectiveness of taletrectinib by decreasing exposure.

Concomitant use may result in serotonin syndrome. Frequent patient evaluation is recommended during treatment initiation and dose adjustment.

Avoid concomitant use. If unavoidable, modify KOMZIFTI administration time to separate dosing.

Reduce atazanavir plasma concentrations by increasing gastric pH, potentially reducing REYATAZ's therapeutic effect.

Concomitant use may result in serotonin syndrome; monitor regularly during initiation and dose adjustment.

Concomitant use may decrease dacomitinib concentrations. Administer VIZIMPRO at least 6 hours before or 10 hours after H2-receptor antagonist.

May increase glucose-lowering effect of glimepiride, increasing susceptibility to hypoglycemia.

May increase the glucose-lowering effect of glipizide, increasing susceptibility to hypoglycemia. Monitor closely.

Concomitant use may cause hyperresponse in gastrin secretion, falsely suggesting gastrinoma. Discontinue at least 2 days before Human Secretin administration.

Reduce gastric acidity and impair itraconazole capsule absorption. Use with caution and monitor antifungal activity.

Reduce gastric acidity and impair ketoconazole absorption from tablets. Ketoconazole should be taken with acidic beverage during coadministration.

Avoid concomitant use with pazopanib. Consider short-acting antacids instead.

Concomitant use decreases selpercatinib plasma concentrations, which may reduce anti-tumor activity. Avoid coadministration; if unavoidable, modify administration time.

Insufficient experience to assess safety and efficacy when administered concurrently. Use not recommended.